Claude Preudhomme

List of Publications by Year
in descending order

447 papers	25,722 citations	5891 81 h-index	9090 144 g-index
460 all docs	460 docs citations	460 times ranked	18477 citing authors

#	Article	IF	Citations
1	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet, The, 2012, 379, 1508-1516.	6.3	839
2	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	0.6	796
3	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1999, 94, 1192-1200.	0.6	682
4	A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 2016, 540, 433-437.	13.7	617
5	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 1994, 84, 3148-3157.	0.6	554
6	Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 2002, 100, 1014-1018.	0.6	502
7	Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002, 100, 2717-2723.	0.6	476
8	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	0.8	462
9	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 2011, 25, 1147-1152.	3.3	430
10	Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study. Journal of Clinical Oncology, 2009, 27, 5195-5201.	0.8	409
11	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 363, 2511-2521.	13.9	362
12	Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion. Blood, 1998, 91, 616-622.	0.6	360
13	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematology,the, 2016, 3, e186-e195.	2.2	359
14	Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 2006, 20, 965-970.	3.3	340
15	Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression. Blood, 1998, 91, 2985-2990.	0.6	337
16	Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia, 2008, 22, 915-931.	3.3	319
17	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	0.6	313
18	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	0.6	305

#	Article	IF	Citations
19	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	0.6	264
20	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2Î±B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000, 96, 2862-2869.	0.6	241
21	Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 1993, 7, 1315-23.	3.3	241
22	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	0.6	232
23	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2017, 35, 185-193.	0.8	227
24	Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica, 2019, 104, 113-119.	1.7	226
25	AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood, 2006, 107, 1166-1173.	0.6	221
26	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	0.6	220
27	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	0.6	214
28	Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(Ï•)-LMC GROUP). Leukemia, 2006, 20, 1061-1066.	3.3	210
29	Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. Journal of Clinical Oncology, 2010, 28, 808-814.	0.8	209
30	Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood, 2005, 106, 3618-3620.	0.6	208
31	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	0.6	198
32	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRAâ€“positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	0.6	195
33	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
34	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 2011, 118, 3824-3831.	0.6	187
35	Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. British Journal of Haematology, 1989, 73, 61-67.	1.2	185
36	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	5.8	177

#	Article	IF	Citations
37	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 1994, 84, 3148-57.	0.6	177
38	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	0.6	169
39	CEBPA point mutations in hematological malignancies. Leukemia, 2005, 19, 329-334.	3.3	164
40	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood, 2009, 113, 5583-5587.	0.6	162
41	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood, 2007, 109, 5129-5135.	0.6	160
42	MOZ is fused top300 in an acute monocytic leukemia with t(8;22). , 2000, 28, 138-144.		157
43	Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood, 2015, 126, 1214-1223.	0.6	157
44	Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood, 2011, 117, e161-e170.	0.6	156
45	Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoÃ¯esis and a high incidence of P53 mutations. Leukemia, 1995, 9, 370-81.	3.3	155
46	High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2006, 24, 1507-1515.	0.8	152
47	Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood, 2004, 103, 442-450.	0.6	141
48	Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leukemia Research, 2014, 38, 751-755.	0.4	141
49	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Research, 1993, 53, 5872-6.	0.4	141
50	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. Blood, 1998, 91, 1008-1015.	0.6	131
51	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	1.7	129
52	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	1.2	127
53	New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia, 2003, 17, 9-16.	3.3	125
54	NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia, 2010, 24, 2023-2031.	3.3	125

#	Article	IF	Citations
55	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	0.6	121
56	C/EBPÎ± regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood, 2010, 116, 5638-5649.	0.6	119
57	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 2012, 26, 1247-1254.	3.3	119
58	p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 1995, 85, 657-663.	0.6	119
59	Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia, 2005, 19, 367-372.	3.3	116
60	Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene, 2000, 19, 2023-2032.	2.6	112
61	Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia, 2002, 16, 1699-1704.	3.3	111
62	Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114, 5271-5278.	0.6	109
63	Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2014, 32, 297-305.	0.8	109
64	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia, 2016, 30, 897-905.	3.3	109
65	Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia, 2005, 19, 792-798.	3.3	108
66	THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES. British Journal of Haematology, 1997, 98, 502-511.	1.2	106
67	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	0.6	105
68	Mutations of the P53 gene in acute myeloid leukaemia. British Journal of Haematology, 1992, 80, 178-183.	1.2	104
69	Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a â€˜real timeâ€™ quantitative RT-PCR assay. Leukemia, 1999, 13, 957-964.	3.3	104
70	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nature Medicine, 2022, 28, 1212-1223.	15.2	104
71	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	3.3	102
72	Genomic Landscape of CXCR4 Mutations in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2016, 22, 1480-1488.	3.2	102

#	Article	IF	Citations
73	Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia, 1992, 6, 246-50.	3.3	102
74	ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia, 1997, 11, 1459-1464.	3.3	101
75	PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia, 2009, 23, 1989-1998.	3.3	101
76	Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica, 2016, 101, 328-335.	1.7	97
77	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 289-300.	0.6	97
78	Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia, 1999, 13, 250-257.	3.3	95
79	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92
80	A Mutation Conferring Resistance to Imatinib at the Time of Diagnosis of Chronic Myelogenous Leukemia. New England Journal of Medicine, 2003, 348, 2265-2266.	13.9	89
81	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Advances, 2022, 6, 998-1003.	2.5	88
82	The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood, 2009, 113, 5090-5093.	0.6	87
83	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet Journal of Rare Diseases, 2016, 11, 49.	1.2	86
84	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia, 2016, 30, 999-1002.	3.3	86
85	Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica, 2012, 97, 890-894.	1.7	85
86	Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. British Journal of Haematology, 2001, 112, 927-935.	1.2	83
87	The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature Communications, 2020, 11, 1044.	5.8	81
88	Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.. Journal of Clinical Oncology, 1995, 13, 812-820.	0.8	80
89	The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia. Medicine (United States), 2013, 92, e1-e9.	0.4	80
90	Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood, 2004, 104, 2467-2474.	0.6	78

#	Article	IF	Citations
91	Is apoptosis a massive process in myelodysplastic syndromes?. British Journal of Haematology, 1996, 95, 368-371.	1.2	77
92	Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	0.8	77
93	Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia, 1997, 11, 294-298.	3.3	76
94	Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia. Cancer, 2009, 115, 3719-3727.	2.0	75
95	BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. Oncotarget, 2012, 3, 490-501.	0.8	75
96	Long-term follow-up ofde novomyelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. British Journal of Haematology, 1997, 98, 983-991.	1.2	74
97	Effect of priming with granulocyteâ€“macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia, 2007, 21, 453-461.	3.3	74
98	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology, 2003, 40, 80-82.	1.8	73
99	M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood, 2003, 101, 1277-1283.	0.6	72
100	A certified plasmid reference material for the standardisation of BCRâ€“ABL1 mRNA quantification by real-time quantitative PCR. Leukemia, 2015, 29, 369-376.	3.3	72
101	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	2.7	72
102	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	2.5	72
103	Rare occurrence of P53 gene mutations in multiple myeloma. British Journal of Haematology, 1992, 81, 440-443.	1.2	71
104	Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8;21) Acute Myeloid Leukemia: A Multicenter Study of 51 Patients. Journal of Clinical Oncology, 2000, 18, 788-788.	0.8	71
105	Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene, 2005, 24, 2441-2448.	2.6	71
106	<scp>MYD</scp>88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	1.2	71
107	MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget, 2014, 5, 6280-6288.	0.8	71
108	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. Journal of Clinical Oncology, 2013, 31, 321-327.	0.8	68

#	Article	IF	Citations
109	Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Journal of Immunology, 2015, 195, 2580-2590.	0.4	68
110	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood, 2008, 111, 3735-3741.	0.6	67
111	High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 2006, 20, 2067-2070.	3.3	64
112	Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 460-468.	1.2	64
113	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2017, 23, 6325-6335.	3.2	64
114	Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia, 2006, 20, 2155-2161.	3.3	62
115	Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics, 2014, 15, 409.	1.2	62
116	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546.	0.6	62
117	Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia, 1994, 8, 1342-9.	3.3	61
118	De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: A subtype of MDS with distinct hematological and prognostic features?. Leukemia Research, 1993, 17, 921-926.	0.4	60
119	Over-expression of the MDM2gene is found in some cases of haematological malignancies. British Journal of Haematology, 1994, 88, 415-418.	1.2	60
120	The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood, 2016, 127, 2157-2160.	0.6	60
121	Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. European Journal of Human Genetics, 2018, 26, 314-323.	1.4	59
122	Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica, 2007, 92, 1238-1241.	1.7	58
123	A randomized phase II trial of azacitidine +/- epoetin-Â in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	1.7	55
124	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	5.8	55
125	Familial CEBPA -mutated acute myeloid leukemia. Seminars in Hematology, 2017, 54, 87-93.	1.8	54
126	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood, 2018, 132, 187-196.	0.6	54

#	Article	IF	Citations
127	MDM2 gene amplification in human breast cancer. European Journal of Cancer, 1994, 30, 982-984.	1.3	53
128	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, 1754-1762.	0.6	52
129	Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research, 2012, 36, 316-323.	0.4	50
130	LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood, 2016, 128, 2694-2707.	0.6	50
131	Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology, 2013, 88, 758-764.	2.0	49
132	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances, 2020, 4, 1942-1949.	2.5	49
133	Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia, 1992, 6, 42-6.	3.3	49
134	Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood, 2022, 140, 756-768.	0.6	48
135	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 2014, 5, 916-932.	0.8	47
136	JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia, 2008, 22, 1454-1455.	3.3	45
137	Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia, 2009, 23, 804-806.	3.3	45
138	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	2.0	45
139	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget, 2015, 6, 22812-22821.	0.8	45
140	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357.	3.3	44
141	Neurofibromatosisâ€1 gene deletions and mutations in de novo adult acute myeloid leukemia. American Journal of Hematology, 2013, 88, 306-311.	2.0	43
142	Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy, 2000, 7, 1312-1316.	2.3	42
143	Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. Leukemia, 2002, 16, 1131-1134.	3.3	42
144	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica, 2015, 100, 780-785.	1.7	42

#	Article	IF	Citations
145	BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia, 2008, 22, 791-799.	3.3	41
146	Acute monocytic leukemia with (8;22)(p11;q13) translocation. Cancer Genetics and Cytogenetics, 1992, 60, 180-182.	1.0	40
147	Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. Phytochemistry, 2008, 69, 2979-2983.	1.4	40
148	GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells. Oncogene, 2012, 31, 1419-1430.	2.6	40
149	SET-NUP214 is a recurrent Î³Î´ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood, 2014, 123, 1860-1863.	0.6	40
150	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. HemaSphere, 2018, 2, e31.	1.2	40
151	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138, 507-519.	0.6	40
152	Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. British Journal of Haematology, 1993, 84, 743-745.	1.2	39
153	Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes. British Journal of Haematology, 1995, 90, 701-706.	1.2	39
154	Genomic Structure and Assignment of theRhoH/TTFSmall GTPase Gene (ARHH) to 4p13 byin SituHybridization. Genomics, 1997, 43, 89-94.	1.3	39
155	Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia, 1997, 11, 1580-1582.	3.3	39
156	Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia, 2011, 25, 1661-1664.	3.3	39
157	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica, 2019, 104, 1565-1571.	1.7	39
158	Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology, 1994, 87, 61-67.	1.2	38
159	Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?. Blood, 2002, 100, 4680-4680.	0.6	38
160	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica, 2015, 100, 1086-95.	1.7	37
161	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology, 2017, 35, 1223-1230.	0.8	37
162	Epidemiology, clinical picture and longâ€term outcomes of FIP1L1â€PDGFRAâ€positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	2.0	37

#	Article	IF	Citations
163	Analysis of p16 gene deletion and point mutation in breast carcinoma. British Journal of Cancer, 1995, 72, 351-353.	2.9	36
164	Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2011, 117, 3696-3697.	0.6	36
165	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, 127, 749-760.	0.6	36
166	Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica, 2018, 103, 822-829.	1.7	36
167	Familial myeloid malignancies with germline TET2 mutation. Leukemia, 2020, 34, 1450-1453.	3.3	36
168	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
169	NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. Haematologica, 2016, 101, e133-e134.	1.7	35
170	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	2.5	35
171	Reactive oxygen species levels control NF-Î¹B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget, 2017, 8, 105510-105524.	0.8	35
172	Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Experimental Hematology, 2011, 39, 195-202.e2.	0.2	34
173	Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia, 2017, 31, 555-564.	3.3	34
174	Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL. Leukemia, 2003, 17, 2056-2057.	3.3	33
175	Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood, 2011, 118, 4331-4337.	0.6	33
176	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood, 2021, 137, 524-532.	0.6	33
177	Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. Leukemia, 1994, 8, 1012-8.	3.3	33
178	B7â€H3 protein expression in acute myeloid leukemia. Cancer Medicine, 2015, 4, 1879-1883.	1.3	32
179	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Reports, 2020, 30, 739-754.e4.	2.9	32
180	Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. Blood, 2021, 137, 1424-1428.	0.6	32

#	Article	IF	Citations
181	The Retinoblastoma Gene (RB-1) Status in Multiple Myeloma: A Report on 35 Cases. Leukemia and Lymphoma, 1995, 18, 497-503.	0.6	30
182	Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. Cancer Genetics and Cytogenetics, 2005, 157, 118-126.	1.0	30
183	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. Current Opinion in Hematology, 2009, 16, 92-97.	1.2	30
184	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplantation, 2017, 52, 539-543.	1.3	30
185	De novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. Leukemia Research, 1990, 14, 1053-1059.	0.4	29
186	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia, 2021, 35, 2720-2724.	3.3	29
187	Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients. International Journal of Laboratory Hematology, 2008, 12, 57-65.	0.2	28
188	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology, 2015, 8, 43-56.	1.0	28
189	Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica, 2021, 106, 3056-3066.	1.7	28
190	CYTOGENETIC AND MOLECULAR REMISSION IN A CASE OF ACUTE MYELOID LEUKAEMIA (AML) WITH INVERSION OF CHROMOSOME 16 (Inv(16)) AND PHILADELPHIA CHROMOSOME (Ph). British Journal of Haematology, 1992, 82, 623-626.	1.2	27
191	Activity of Ladanein on Leukemia Cell Lines and Its Occurrence inMarrubium vulgare. Planta Medica, 2010, 76, 86-87.	0.7	27
192	Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. Oncotarget, 2015, 6, 36269-36277.	0.8	27
193	CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Medicine, 2019, 8, 1279-1288.	1.3	27
194	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia. Blood, 2014, 124, 117-117.	0.6	27
195	p16^{ink4a}Gene and Hematological Malignancies. Leukemia and Lymphoma, 1996, 22, 11-24.	0.6	26
196	Homozygous G20210A Transition in the Prothrombin Gene Associated with Severe Venous Thrombotic Disease: Two Cases in a French Family. Thrombosis and Haemostasis, 1998, 80, 1027-1028.	1.8	26
197	The severity of FIP1L1â€“PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia, 2007, 21, 2428-2432.	3.3	26
198	Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?. Blood, 2010, 116, 6145-6146.	0.6	26

#	Article	IF	Citations
199	Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers, 2019, 11, 1323.	1.7	26
200	The Need for a Consensus Nextâ€generation Sequencing Panel for Mature Lymphoid Malignancies. HemaSphere, 2019, 3, e169.	1.2	26
201	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget, 2013, 4, 1582-1591.	0.8	26
202	bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia, 1995, 9, 726-30.	3.3	26
203	Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. British Journal of Haematology, 2000, 110, 591-598.	1.2	25
204	Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes and Cancer, 2008, 47, 915-918.	1.5	25
205	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. Cancers, 2020, 12, 1992.	1.7	24
206	Chromosomal Minimal Critical Regions in Therapy-Related Leukemia Appear Different from Those of De Novo Leukemia by High-Resolution aCGH. PLoS ONE, 2011, 6, e16623.	1.1	24
207	The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia, 2009, 23, 271-278.	3.3	23
208	Which AML subsets benefit from leukemic cell priming during chemotherapy? Longâ€term analysis of the ALFAâ€9802 GMâ€CSF study. Cancer, 2010, 116, 1725-1732.	2.0	23
209	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Cancer Research, 2014, 74, CT231-CT231.	0.4	23
210	Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1994, 8, 1589-91.	3.3	23
211	Transfer of p16 inka /CDKN2 gene in leukaemic cell lines inhibits cell proliferation. British Journal of Haematology, 1996, 95, 291-298.	1.2	22
212	Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. American Journal of Hematology, 2014, 89, 399-403.	2.0	22
213	Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia. Haematologica, 2016, 101, e365-e368.	1.7	22
214	NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica, 2018, 103, e455-e457.	1.7	22
215	p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 1994, 84, 3148-3157.	0.6	22
216	Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. Bone Marrow Transplantation, 2005, 35, 767-773.	1.3	21

#	Article	IF	Citations
217	Linezolid induces ring sideroblasts. Haematologica, 2013, 98, e138-e140.	1.7	21
218	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1â€RUNX1T1 fusion quantification on genomic DNA. American Journal of Hematology, 2014, 89, 610-615.	2.0	21
219	Therapy Related Myelodysplastic Syndrome and Leukemia with no â€œUnfavourableâ€•Cytogenetic Findings have a Good Response to Intensive Chemotherapy: A Report on 15 Cases. Leukemia and Lymphoma, 1991, 5, 117-125.	0.6	20
220	Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. , 1996, 15, 191-194.		20
221	Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia, 2010, 24, 1386-1388.	3.3	20
222	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences, 2020, 21, 5626.	1.8	20
223	Final Analysis of the ALFA 0701 Study. Blood, 2014, 124, 376-376.	0.6	20
224	Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget, 2016, 7, 62377-62385.	0.8	20
225	Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 1994, 8, 998-1004.	3.3	20
226	Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia, 1993, 7, 1291-3.	3.3	20
227	Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia, 2004, 18, 354-355.	3.3	19
228	The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication. Blood, 2009, 114, 4601-4602.	0.6	19
229	Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia, 2010, 24, 476-480.	3.3	19
230	Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. British Journal of Haematology, 2015, 170, 285-287.	1.2	19
231	Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget, 2016, 7, 2889-2909.	0.8	19
232	Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Review of Hematology, 2016, 9, 1189-1202.	1.0	19
233	UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	0.6	19
234	Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Leukemia, 2006, 20, 433-436.	3.3	18

#	Article	IF	Citations
235	High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. Leukemia Research, 2017, 53, 1-7.	0.4	18
236	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	3.3	18
237	Detection of a new heterozygous germline <scp>ETV</scp>6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. European Journal of Haematology, 2018, 100, 104-107.	1.1	18
238	Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematological Oncology, 2018, 36, 422-428.	0.8	18
239	p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?. Haematologica, 1999, 84, 1075-80.	1.7	18
240	Expression of Lung Resistance Protein and Correlation with Other Drug Resistance Proteins and Outcome in Myelodysplastic Syndromes. Leukemia and Lymphoma, 1998, 29, 547-551.	0.6	17
241	Correspondence. Leukemia Research, 1999, 23, 415-416.	0.4	17
242	Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leukemia Research, 2011, 35, 448-458.	0.4	17
243	Multiâ€loci diagnosis of acute lymphoblastic leukaemia with highâ€throughput sequencing and bioinformatics analysis. British Journal of Haematology, 2016, 173, 413-420.	1.2	17
244	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget, 2014, 5, 4384-4391.	0.8	17
245	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
246	Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1â€“PRDM16 fusion in a case of progressive chronic myeloid leukemia: A complex chromosomal rearrangement of underestimated frequency in disease progression?. Genes Chromosomes and Cancer, 2008, 47, 1110-1117.	1.5	16
247	Tolerability and efficacy of pegylated interferonâ€Î±â€2a in combination with imatinib for patients with chronicâ€phase chronic myeloid leukemia. Cancer, 2013, 119, 4284-4289.	2.0	16
248	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, 2015, 100, e196-e199.	1.7	16
249	Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia, 2016, 30, 1416-1418.	3.3	16
250	Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.. Blood, 2007, 110, 162-162.	0.6	16
251	The Role of Intensive Chemotherapy in Myelodysplastic Syndromes. Leukemia and Lymphoma, 1992, 8, 43-49.	0.6	15
252	Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFÎ²-MYH11 transcript: report of two new cases. Leukemia, 2002, 16, 150-151.	3.3	15

#	Article	IF	Citations
253	Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leukemia Research, 2014, 38, 662-665.	0.4	15
254	Incidence of <scp>ATRX</scp> mutations in myelodysplastic syndromes, the value of microcytosis. American Journal of Hematology, 2015, 90, 737-738.	2.0	15
255	Long-term outcome of imatinib 400â€‰mg compared to imatinib 600â€‰mg or imatinib 400â€‰mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, 35, 2332-2345.	3.3	15
256	Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. Expert Opinion on Therapeutic Targets, 2021, 25, 299-309.	1.5	15
257	SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget, 2018, 9, 6478-6489.	0.8	15
258	Good Predictive Value of Combined Cytogenetic and Molecular Follow Up in Chronic Myelogenous Leukemia After Non T-cell Depleted Allogeneic Bone Marrow Transplantation: A Report on 38 Consecutive Cases. Leukemia and Lymphoma, 1995, 18, 265-271.	0.6	14
259	Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay. Leukemia, 1999, 13, 818-823.	3.3	14
260	Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. British Journal of Haematology, 2002, 118, 1082-1086.	1.2	14
261	Mutation in RAP1 is a rare event in myelodysplastic syndromes. Leukemia, 2005, 19, 1678-1680.	3.3	14
262	Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. Leukemia, 2005, 19, 1991-1992.	3.3	14
263	IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. Leukemia, 2005, 19, 2337-2338.	3.3	14
264	The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?. Leukemia, 2007, 21, 193-194.	3.3	14
265	Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules. Cancer, 2015, 121, 490-497.	2.0	14
266	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatric Hematology and Oncology, 2017, 34, 425-427.	0.3	14
267	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	0.6	14
268	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica, 2019, 104, 1150-1155.	1.7	14
269	Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leukemia and Lymphoma, 2019, 60, 1827-1830.	0.6	14
270	Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50â€“70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA). Blood, 2011, 118, 6-6.	0.6	14

#	Article	IF	Citations
271	Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology, 2022, 61, 4355-4363.	0.9	14
272	Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia, 2007, 21, 2376-2377.	3.3	13
273	Acute myeloid leukemia with translocation t(3;5): new molecular insights. Haematologica, 2013, 98, e52-e54.	1.7	13
274	Absence of CALR mutations in JAK2 -negative polycythemia. Haematologica, 2017, 102, e15-e16.	1.7	13
275	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	1.2	13
276	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2Î±B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000, 96, 2862-2869.	0.6	13
277	Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. Journal of Clinical Oncology, 2008, 26, 7088-7088.	0.8	13
278	p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 1995, 85, 657-63.	0.6	13
279	Recurrent in-frame insertion in C/EBPÎ± TAD2 region is a polymorphism without prognostic value in AML. Leukemia, 2008, 22, 655-657.	3.3	12
280	Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. Leukemia, 2011, 25, 1918-1921.	3.3	12
281	5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies. European Journal of Cancer, 2014, 50, 196.	1.3	12
282	Classification of <scp>CEBPA</scp> mutated acute myeloid leukemia by <scp>GATA2</scp> mutations. American Journal of Hematology, 2015, 90, E93-4.	2.0	12
283	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Advances, 2021, 5, 5258-5268.	2.5	12
284	Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group. Blood, 2014, 124, 1062-1062.	0.6	12
285	A randomised phase <scp>II</scp> study of azacitidine (<scp>AZA</scp>) alone or with Lenalidomide (<scp>LEN</scp>), Valproic acid (<scp>VPA</scp>) or Idarubicin (<scp>IDA</scp>) in <scp>higherâ€Risk MDS</scp> or low blast <scp>AML</scp>: <scp>GFM</scp>'s â€œpick a winnerâ€•trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	1.2	12
286	Unlike AML1, CBFÎ² gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. Blood, 2002, 99, 3848-3850.	0.6	11
287	Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia. Leukemia, 2003, 17, 1677-1678.	3.3	11
288	Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia. Current Research in Translational Medicine, 2020, 68, 37-42.	1.2	11

#	Article	IF	Citations
289	Humulane and Germacrane Sesquiterpenes from Ferula lycia. Journal of Natural Products, 2010, 73, 780-783.	1.5	10
290	Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplantation, 2012, 47, 1436-1441.	1.3	10
291	Calibration of BCRâ€“ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale. Clinical Biochemistry, 2014, 47, 1333-1336.	0.8	10
292	A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. Haematologica, 2018, 103, e575-e577.	1.7	10
293	Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia, 2019, 33, 1814-1816.	3.3	10
294	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. Blood, 2008, 112, 753-753.	0.6	10
295	Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS. Blood, 2010, 116, 439-439.	0.6	10
296	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1999, 94, 1192-1200.	0.6	10
297	Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. Leukemia Research, 1994, 18, 365-371.	0.4	9
298	Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. Leukemia, 2006, 20, 2178-2181.	3.3	9
299	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leukemia Research, 2012, 36, 1112-1118.	0.4	9
300	Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis. Leukemia Research, 2012, 36, 1330-1333.	0.4	9
301	Quantification of JAK2V617F mutation by next-generation sequencing technology. American Journal of Hematology, 2013, 88, 536-537.	2.0	9
302	Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. Annals of Hematology, 2015, 94, 1247-1249.	0.8	9
303	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9
304	Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. Haematologica, 2018, 103, e274-e276.	1.7	9
305	Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. British Journal of Haematology, 2020, 189, e119-e122.	1.2	9
306	Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology, 2003, 40, 80-82.	1.8	9

#	Article	IF	Citations
307	Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. European Journal of Cancer, 1993, 29, 1476-1478.	1.3	8
308	Significance of Circulating Plasma Cells in Multiple Myeloma. Leukemia and Lymphoma, 1994, 14, 491-496.	0.6	8
309	Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype. Leukemia, 2001, 15, 1054-1059.	3.3	8
310	A case of refractory anemia with 17pâ^' syndrome following azathioprine treatment for heart transplantation. Leukemia, 2004, 18, 878-878.	3.3	8
311	Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm withBCR-JAK2fusion transcript. European Journal of Haematology, 2016, 97, 399-402.	1.1	8
312	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. Leukemia, 2018, 32, 1878-1882.	3.3	8
313	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Advances, 2020, 4, 5322-5335.	2.5	8
314	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Leukemia, 2021, 35, 724-736.	3.3	8
315	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. Haematologica, 2021, 106, 908-912.	1.7	8
316	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica, 2021, 106, 1767-1769.	1.7	8
317	Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. Leukemia, 1994, 8, 2241-2.	3.3	8
318	T-Cell Acute Lymphoblastic Leukemia Occurring in the Course of B Cell Chronic Lymphocytic Leukemia: A Case Report. Leukemia and Lymphoma, 1995, 18, 361-364.	0.6	7
319	Slow relapse in acute myeloid leukemia with inv(16) or t(16;16). Haematologica, 2009, 94, 1466-1467.	1.7	7
320	Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. Leukemia, 2010, 24, 205-209.	3.3	7
321	Recommandations duÂgroupe FI-LMC pourÂlaÂprise enÂcharge desÂpatients prÃ©sentant desÂmutations duÂdomaine tyrosine kinase deÂBCR-ABL dansÂlesÂhÃ©mopathies malignes ÂÂchromosome Philadelphie. Hematologie, 2010, 16, 65-79.	0.0	7
322	Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemiaâ€"an unusual association: another cause of cytopenia in PNH. Annals of Hematology, 2015, 94, 1759-1760.	0.8	7
323	Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 2018, 32, 1856-1860.	3.3	7
324	Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. Journal of Visualized Experiments, 2018, , .	0.2	7

#	Article	IF	Citations
325	Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal Conventional Cytogenetics.. Blood, 2004, 104, 2442-2442.	0.6	7
326	HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML. Blood, 2015, 126, 1307-1307.	0.6	7
327	C/EBPA methylation is common in T-ALL but not in M0 AML. Blood, 2009, 113, 1864-1866.	0.6	6
328	Diagnosis of intrachromosomal amplification of chromosome 21 (<scp>iAMP</scp>21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia. Clinical Case Reports (discontinued), 2015, 3, 814-816.	0.2	6
329	TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML). Leukemia Research, 2017, 56, 21-28.	0.4	6
330	Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. HemaSphere, 2021, 5, e552.	1.2	6
331	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. Blood, 2012, 120, 1399-1399.	0.6	6
332	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	0.6	6
333	Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. Leukemia, 2022, 36, 656-663.	3.3	6
334	A multiparametric niche-like drug screening platform in acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	2.8	6
335	Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. Leukemia, 1998, 12, 238-241.	3.3	5
336	Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): Evolution on hypomethylating agent therapy. Leukemia Research, 2011, 35, e203-e205.	0.4	5
337	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hautsâ€deâ€France AML observatory. American Journal of Hematology, 2019, 94, E24-E27.	2.0	5
338	Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 438-445.	0.6	5
339	17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ. Blood, 1998, 91, 1008-1015.	0.6	5
340	Role of IRF4 in resistance to immunomodulatory (IMid) compoundsÂ® in WaldenstrÃ¶mâ€™s macroglobulinemia. Oncotarget, 2017, 8, 112917-112927.	0.8	5
341	Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis. Leukemia, 1993, 7, 1054-7.	3.3	5
342	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4

#	Article	IF	Citations
343	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. Leukemia Research, 2018, 71, 67-74.	0.4	4
344	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia, 2018, 32, 2066-2069.	3.3	4
345	Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapyâ€refractory Bâ€cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1â€ABL2 Fusion. HemaSphere, 2019, 3, e193.	1.2	4
346	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88.	1.7	4
347	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	1.7	4
348	Molecular Heterogeneity of the FIP1L1-PDGFRA Fusion Gene in Chronic Eosinophilic Leukemia (CEL) and Systemic Mastocytosis with Eosinophilia (SME): A Study of 43 Cases.. Blood, 2004, 104, 2428-2428.	0.6	4
349	Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.. Blood, 2007, 110, 542-542.	0.6	4
350	Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 163-163.	0.6	4
351	Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC). Blood, 2012, 120, 168-168.	0.6	4
352	De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory. Blood, 2016, 128, 4013-4013.	0.6	4
353	A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. Oncotarget, 2018, 9, 33869-33870.	0.8	4
354	Incidence and Prognosis of RTKs and RAS Mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials.. Blood, 2004, 104, 2022-2022.	0.6	4
355	Very low incidence of p53 antibodies in adult nonâ€Hodgkin's lymphoma and multiple myeloma. British Journal of Haematology, 1998, 100, 184-186.	1.2	3
356	Chromosomal insertion involving MLL in childhood acute myeloblastic leukemia (M4). Cancer Genetics and Cytogenetics, 2004, 150, 153-155.	1.0	3
357	Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia. Leukemia and Lymphoma, 2005, 46, 925-927.	0.6	3
358	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. Leukemia, 2021, 35, 893-896.	3.3	3
359	Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine. Blood, 2012, 120, 1706-1706.	0.6	3
360	MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. Blood, 2020, 136, 31-32.	0.6	3

#	Article	IF	Citations
361	Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. Blood Advances, 2022, 6, 2773-2777.	2.5	3
362	The Arg200Trp Mutation in the Human Tissue Factor Gene. Thrombosis and Haemostasis, 2002, 87, 540-541.	1.8	2
363	TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. Annales De GÃ©nÃ©tique, 2002, 45, 165-168.	0.4	2
364	New-generation sequencing (NGS) in hematologic oncology laboratories. Hematologie, 2013, 19, 112-122.	0.0	2
365	Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. Leukemia Research, 2015, 39, 1214-1219.	0.4	2
366	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. Blood, 2018, 132, 993-993.	0.6	2
367	A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients. Blood, 2018, 132, 2765-2765.	0.6	2
368	MYD88 L265P Mutation in Waldenstrom's Macroglogulinemia. Blood, 2012, 120, 1307-1307.	0.6	2
369	Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM). Blood, 2012, 120, 297-297.	0.6	2
370	BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. Blood, 2012, 120, 701-701.	0.6	2
371	Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA). Blood, 2014, 124, 482-482.	0.6	2
372	Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. Blood, 2016, 128, 1083-1083.	0.6	2
373	BACH2 promotes indolent clinical presentation in WaldenstrÃ¶m macroglobulinemia. Oncotarget, 2017, 8, 57451-57459.	0.8	2
374	Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group. Leukemia, 2022, 36, 1390-1400.	3.3	2
375	P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q. Leukemia Research, 2013, 37, S32-S33.	0.4	1
376	P-004 SETBP1 mutations in 658 patients with myeldodysplastic syndromes, chronic myelomonocytic leukemia and secondary AML. Leukemia Research, 2013, 37, S24.	0.4	1
377	Place de la biologie molÃ©culaire pour le diagnostic et le suivi des leucÃ©mies aiguÃ«s. Revue Francophone Des Laboratoires, 2015, 2015, 51-64.	0.0	1
378	Shared clonal IGH rearrangement in BCPâ€ALL occurring after CLL: pitfalls and implications for MRD monitoring. British Journal of Haematology, 2020, 191, 506-509.	1.2	1

#	Article	IF	Citations
379	Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype. Leukemia and Lymphoma, 2020, 61, 1772-1774.	0.6	1
380	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia, 2020, 34, 2230-2233.	3.3	1
381	Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. , 0, .		1
382	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. Blood, 2018, 132, 2806-2806.	0.6	1
383	A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4007-4007.	0.6	1
384	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Blood, 2019, 134, 877-877.	0.6	1
385	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. Blood, 2004, 104, 1507-1507.	0.6	1
386	PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. Blood, 2007, 110, 2806-2806.	0.6	1
387	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). Blood, 2012, 120, 3811-3811.	0.6	1
388	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. Blood, 2013, 122, 2613-2613.	0.6	1
389	The B7-H3 Protein In Acute Myeloid Leukemia. Blood, 2013, 122, 2620-2620.	0.6	1
390	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. Blood, 2013, 122, 658-658.	0.6	1
391	Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis. Blood, 2014, 124, 1083-1083.	0.6	1
392	Procoagulant Platelet-Derived Microparticles Are Lower in Calreticulin-Than in-JAK2-Mutated Essential Thrombocythemia. Blood, 2014, 124, 110-110.	0.6	1
393	Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group. Blood, 2014, 124, 2327-2327.	0.6	1
394	Results of the â€œEvaluation of NGS in AML-Diagnostics (ELAN)â€•Study â€“ an Inter-Laboratory Comparison Performed in 10 European Laboratories. Blood, 2014, 124, 2374-2374.	0.6	1
395	NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience. Blood, 2014, 124, 533-533.	0.6	1
396	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	0.6	1

#	Article	IF	Citations
397	Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation. Blood, 2015, 126, 3833-3833.	0.6	1
398	TP53 Mutation in Waldenstrom Macroglobulinemia. Blood, 2016, 128, 4092-4092.	0.6	1
399	Prognostic Impact of Wilms Tumor 1 Single Nucleotide Polymorphism rs16754 In Older Patients with Acute Myeloid Leukemia. Blood, 2010, 116, 2701-2701.	0.6	1
400	Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA). Blood, 2011, 118, 253-253.	0.6	1
401	Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS). Blood, 2014, 124, 3266-3266.	0.6	1
402	French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hematologie, 2015, 21, 28-45.	0.0	1
403	NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group. Blood, 2015, 126, 2581-2581.	0.6	1
404	Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood, 2021, 138, 612-612.	0.6	1
405	Place deÂlaÂbiologie molÃ©culaire dansÂlâ€™Ã©valuation pronostique desÂpatients atteints deÂleucÃ©mie aiguÃ« myÃ©loÃ¯de. Hematologie, 2009, 15, 426-443.	0.0	0
406	C020 Prevalence of TET2 mutations in MDS. Leukemia Research, 2009, 33, S43-S44.	0.4	0
407	Implication of IDH1 and IDH2 gene mutations in acute myeloid leukemia. Hematologie, 2011, 17, 132-144.	0.0	0
408	Wilmsâ€™ Tumor 1 (WT1) and acute leukemia. Hematologie, 2011, 17, 40-60.	0.0	0
409	French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment. Hematologie, 2015, 21, 46-59.	0.0	0
410	Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing. Value in Health, 2016, 19, A693.	0.1	0
411	A Difficult Diagnosis of a Myelodysplastic Syndrome/Myeloproliferative Neoplasm in its Limiting form and Interest of Next Generation Sequencing. Journal of Blood & Lymph, 2018, 08, .	0.0	0
412	Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.. Blood, 2007, 110, 2847-2847.	0.6	0
413	Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience.. Blood, 2007, 110, 3496-3496.	0.6	0
414	New sesquiterpene esters and a saponin from Ferula elaeochytris and their cytotoxic evaluation against leukemia cell lines. Planta Medica, 2008, 74, .	0.7	0

#	Article	IF	Citations
415	Incidence and Prognostic Impact of SNPs Regulating PU.1 Gene Expression in AML. Blood, 2008, 112, 2949-2949.	0.6	0
416	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. Blood, 2010, 116, 4171-4171.	0.6	0
417	A Recurrent Pattern of Acquired Genomic Abnormalities In Myelodysplasia and Leukemia of Fanconi Anemia Includes Cryptic RUNX1/AML1 abnormalities. Blood, 2010, 116, 975-975.	0.6	0
418	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410.	0.6	0
419	SNP Array Analysis in Acute Myeloid Leukemia Reveals Frequent and Recurrent Acquired Genetic Alterations Linked to Prognosis: a Study of the ALFA Group. Blood, 2011, 118, 2533-2533.	0.6	0
420	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	0.6	0
421	Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.. Blood, 2012, 120, 2809-2809.	0.6	0
422	B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstrol̂m Macroglobulinemia. Blood, 2012, 120, 1288-1288.	0.6	0
423	DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.. Blood, 2012, 120, 2392-2392.	0.6	0
424	Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML). Blood, 2012, 120, 309-309.	0.6	0
425	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. Blood, 2013, 122, 1353-1353.	0.6	0
426	Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing. Blood, 2013, 122, 740-740.	0.6	0
427	Presence of inv (16) May Be One of the Only â€œFavorableâ€•Prognostic Factors in AML: A Report on 16 Cases. Hamatologie Und Bluttransfusion, 1994, , 602-605.	0.0	0
428	Epidemiology of Adults AML in Nord-Pas De Calais and Picardy. Blood, 2014, 124, 2281-2281.	0.6	0
429	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4629-4629.	0.6	0
430	Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics. Blood, 2014, 124, 2324-2324.	0.6	0
431	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360.	0.6	0
432	TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy. Blood, 2014, 124, 68-68.	0.6	0

#	Article	IF	Citations
433	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. Blood, 2014, 124, 1007-1007.	0.6	0
434	Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group. Blood, 2015, 126, 2568-2568.	0.6	0
435	Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2015, 126, 4933-4933.	0.6	0
436	Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 3952-3952.	0.6	0
437	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861.	0.6	0
438	Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial. Blood, 2016, 128, 1676-1676.	0.6	0
439	French Group of Cellular Hematology, Aix en Provence, 17-19ÂMay 2017. Hematologie, 2017, 23, 293-297.	0.0	0
440	CytomÃ©trie en flux. , 2018, , 27-39.		0
441	Maladie rÃ©siduelle molÃ©culaire. , 2018, , 301-306.		0
442	Exploration des prolifÃ©rations lymphoÃ¯des. , 2018, , 291-299.		0
443	Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC). Blood, 2018, 132, 4009-4009.	0.6	0
444	Chemotherapy Treatment Doesn't Beneficiate to a Group of Elderly AML Patients with Absence of Complex Karyotype and Circulating Blasts. Blood, 2018, 132, 2679-2679.	0.6	0
445	Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients. Blood, 2019, 134, 840-840.	0.6	0
446	Optical Mapping, a Promising Alternative to Gold Standard Cytogenetic Approaches in Acute Lymphoblastic Leukemias: A Blind Comparison on 10 Patients. Blood, 2020, 136, 39-40.	0.6	0
447	Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients. Blood, 2020, 136, 22-23.	0.6	0